Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1-Bad-Bak pathway in peritoneal carcinomatosis

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Song, X ^a   Dilly, A K ^a   Kim, S Y ^a   Choudry, H A ^a   Lee, Y J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; MITOMYCIN; P70 S6 RIBOSOMAL KINASE 1; PHOSPHOTRANSFERASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BCL XL; RAPAMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; BAD PROTEIN, HUMAN; BAK1 PROTEIN, HUMAN; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; S6 KINASE;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARCINOMATOSIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CYTOTOXICITY; EMBOLIZATION COIL; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; MTS ASSAY; NICK END LABELING; NONHUMAN; OLIGOMERIZATION; PERITONEAL CARCINOMATOSIS; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; AGONISTS; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PERITONEAL NEOPLASMS; SECONDARY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; MITOMYCIN; PERITONEAL NEOPLASMS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS;

EID: 84903796005     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.242     Document Type: Article

References (48)

1. Seidl C, Essler M. Radioimmunotherapy for peritoneal cancers. Immunotherapy 2013; 5: 395-405.
2. Knorr C, Reingruber B, Meyer T, Hohenberger W, Stremmel C. Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities. Int J Colorectal Dis 2004; 19: 181-187.
3. Ceelen WP. Current management of peritoneal carcinomatosis from colorectal cancer. Minerva Chir 2013; 68: 77-86.
4. Pirnia F, Schneider E, Betticher DC, Borner MM. Mitomycin C induces apoptosis and caspase-8 and-9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ 2002; 9: 905-914.
5. Wu KY, Wang HZ, Hong SJ. Mechanism of mitomycin-induced apoptosis in cultured corneal endothelial cells. Mol Vis 2008; 14: 1705-1712.
6. Van der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2011; 68: 147-156.
7. Cohen MS, Al-Kasspooles MF, Williamson SK, Henry D, Broward M, Roby KF. Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo. Ann Surg Oncol 2010; 17: 296-303.
8. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004; 15: 478-483.
9. Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G. Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. Anticancer Res 2013; 33: 2743-2746.
10. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005; 11: 353-361.
11. Tee AR, Proud CG. Staurosporine inhibits phosphorylation of translational regulators linked to mTOR. Cell Death Differ 2001; 8: 841-849.
12. Tee AR, Proud CG. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 2000; 19: 3021-3031.
13. Ramanathan A, Schreiber SL. Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci USA 2009; 106: 22229-22232.
14. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105: 17414-17419.
15. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008; 17: 1717-1734.
16. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671-688.
17. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251.
18. Tandon P, Gallo CA, Khatri S, Barger JF, Yepiskoposyan H, Plas DR. Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc Natl Acad Sci USA 2011; 108: 2361-2365.
19. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275: 661-665.
20. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-267.
21. Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE et al. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. Embo J 1995; 14: 5279-5287.
22. Danial NN. BAD: undertaker by night, candyman by day. Oncogene 2008; 27(Suppl 1): S53-S70.
23. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.
24. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-730.
25. Carethers JM, Pham TT. Mutations of transforming growth factor beta 1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines. In Vivo 2000; 14: 13-20.
26. Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, Chapman J et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 2010; 431: 245-255.
27. Dennis PB, Pullen N, Kozma SC, Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycininsensitive kinase kinases. Mol Cell Biol 1996; 16: 6242-6251.
28. Schalm SS, Blenis J. Identification of a conserved motif required for mTOR signaling. Curr Biol 2002; 12: 632-639.
29. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 2005; 65: 5325-5336.
30. Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM et al. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 2011; 117: 361-371.
31. Wagner OJ, Inglin RA, Bisch-Knaden S, Mettler D, Borner M, Candinas D et al. Sirolimus and intraoperative hyperthermic peritoneal chemoperfusion with mitomycin-C do not impair healing of bowel anastomoses. Transpl Int 2008; 21: 554-563.
32. Werner D, Atmaca A, Pauligk C, Pustowka A, Jager E, Al-Batran SE. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med 2013; 2: 325-333.
33. Shang YC, Chong ZZ, Wang S, Maiese K. Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) 2012; 4: 187-201.
34. Wang Y, Hu Z, Liu Z, Chen R, Peng H, Guo J et al. MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1. Autophagy 2013; 9: 2069-2086.
35. Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H et al. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Invest 2010; 90: 762-773.
36. Maiese K, Chong ZZ, Shang YC, Wang S. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets 2012; 16: 1203-1214.
37. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009; 8: 3831-3837.
38. Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 2009; 13: 1193-1203.
39. Dormond O, Madsen JC, Briscoe DM. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem 2007; 282: 23679-23686.
40. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001; 98: 9666-9670.
41. Ismail HM. Overexpression of s6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients' survival. J Oncol 2012; 2012: 416927.
42. Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 2004; 23: 1889-1899.
43. Song X, Kim SY, Lee YJ. The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer. Mol Cancer Res 2012; 10: 1567-1579.
44. Taghiyev AF, Guseva NV, Harada H, Knudson CM, Rokhlin OW, Cohen MB. Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP. Mol Cancer Res 2003; 1: 500-507.
45. Masters SC, Yang H, Datta SR, Greenberg ME, Fu H. 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharmacol 2001; 60: 1325-1331.
46. Aluvila S, Mandal T, Hustedt E, Fajer P, Choe JY, Oh KJ. Organization of the mitochondrial apoptotic BAK pore: oligomerization of the BAK homodimers. J Biol Chem 2013; 11: 44.
47. Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 2011; 17: 6356-6366.
48. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 2013; 4: 2427.